Mind Medicine announced the appointment of Matt Wiley as its Chief Commercial Officer (CCO). In his new role, Mr. Wiley will serve as a member of the executive team, overseeing the Company?s commercial vision and strategy as it prepares for the potential launch of its first product, MM120 orally disintegrating tablet (ODT) for generalized anxiety disorder (GAD) and major depressive disorder (MDD). Mr. Wiley has more than 25 years of sales, marketing, and strategic leadership experience across multiple specialty product launches.
He joins MindMed from BioXcel Therapeutics, where he served as CCO overseeing the launch of the company?s first acute treatment of agitation associated with schizophrenia and bipolar disorder. Prior to BioXcel, Mr. Wiley served as CCO at VYNE Therapeutics, overseeing all commercial objectives related to the launch of the company?s first two dermatology products. Before this, he served as Vice President of Marketing and Business Unit Lead for Jazz Pharmaceuticals?
sleep medicine unit, where he led commercial strategies for the company?s treatments for narcolepsy and sleep apnea and developed the successful growth strategy for XYREM® for narcolepsy, which achieved blockbuster status over his tenure. He also served as Vice President of Marketing at Azur Pharma, supporting the startup of U.S. operations and the company?s acquisition by Jazz Pharmaceuticals. In addition, Mr. Wiley held roles of increasing responsibility at Cephalon, Salix Pharmaceuticals, and MGI Pharma.
He holds a Bachelor of Arts in English from Syracuse University.
